Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 8/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075932 | 0.92 | FEN1 (0.39) | KDM1AMAPTFEN1ALOX5APAPP | |
| SCHEMBL26075942 | 0.87 | DHFR (0.39) | KDM1AFEN1ALOX5APAPPMCHR1 | |
| SCHEMBL26075314 | 0.86 | APP (0.43) | KDM1AAPPDHFRESR1ESR2 | |
| SCHEMBL26075424 | 0.86 | KIF11 (0.43) | FEN1ALOX5APAPPMCHR1AKR1C3 | |
| SCHEMBL23590261 | 0.85 | DHODH (0.47) | FEN1ALOX5APAPPAKR1C3AKR1C2 | |
| SCHEMBL26075335 | 0.85 | ACP1 (0.50) | MAPTFEN1ALOX5APAPP | |
| SCHEMBL26075893 | 0.84 | ESR1 (0.37) | KDM1AAPPTOP1ESR1ESR2 | |
| SCHEMBL23590307 | 0.84 | TOP1 (0.42) | FEN1ALOX5APAPPAKR1C3AKR1C2 | |
| SCHEMBL26075920 | 0.83 | ACP1 (0.44) | MAPTFEN1ALOX5APTOP1ESR1 | |
| SCHEMBL26075432 | 0.83 | FEN1 (0.42) | FEN1ALOX5APAPPMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | KDM1A 919/4885MAPT 2689/4885FEN1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.